LONG-TERM OUTCOMES OF RETINAL DEGENERATIVE DISORDER TREATMENT WITH PEPTIDE BIOREGULATORS

Aim. To analyze long-term outcomes and efficacy of retinal degeneration treatment with Retinalamin.Patients and methods. Group I included 20 patients (40 eyes) with pigmentary retinal dystrophy (15 patients, 30 eyes) and retinal abiotrophy (5 patients, 10 eyes) who received treatment with Retinalami...

Full description

Saved in:
Bibliographic Details
Main Authors: M. I. Razumovskiy, K. M. Pavlyuchenko, A. M. Razumovskaya
Format: Article
Language:Russian
Published: Ophthalmology Publishing Group 2015-07-01
Series:Oftalʹmologiâ
Subjects:
Online Access:https://www.ophthalmojournal.com/opht/article/view/242
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849400572242821120
author M. I. Razumovskiy
K. M. Pavlyuchenko
A. M. Razumovskaya
author_facet M. I. Razumovskiy
K. M. Pavlyuchenko
A. M. Razumovskaya
author_sort M. I. Razumovskiy
collection DOAJ
description Aim. To analyze long-term outcomes and efficacy of retinal degeneration treatment with Retinalamin.Patients and methods. Group I included 20 patients (40 eyes) with pigmentary retinal dystrophy (15 patients, 30 eyes) and retinal abiotrophy (5 patients, 10 eyes) who received treatment with Retinalamin for 5‑7 years. Group II included 11 patients (22 eyes) with pigmentary retinal dystrophy (9 patients, 18 eyes) and retinal abiotrophy (2 patients, 4 eyes) who received treatment with Retinalamin for 23‑25 years. Group III (controls) included 15 patients (30 eyes) with pigmentary retinal dystrophy (11 patients, 22 eyes) and retinal abiotrophy (4 patients, 8 eyes) who received traditional treatment (vasodilators, angioprotectors, antisclerotic agents, vitamins) for 25 years. Standard ophthalmological examination, i.e., visual acuity measurement, visual field test, refractometry, biomicroscopy, ophthalmoscopy, was performed.Results. First course of treatment with Retinalamin improved vision in 58.1 % of retinal degeneration patients. Visual fields improved in 64.5 % of cases. Repeated treatment courses (1‑2 times a year) for 23‑25 years preserved residual vision in 55.6 % of patients and object vision in 11.1 % of cases. In retinal abiotrophy patients, residual vision preserved in 100 % of cases.Conclusions. In retinal degenerations, Retinalamin improves vision and visual fields and decreases total area of absolute scotomas even after the first treatment course as well as preserves vision in prolonged use.
format Article
id doaj-art-3e4375ed842f456a914ca93d15583d0b
institution Kabale University
issn 1816-5095
2500-0845
language Russian
publishDate 2015-07-01
publisher Ophthalmology Publishing Group
record_format Article
series Oftalʹmologiâ
spelling doaj-art-3e4375ed842f456a914ca93d15583d0b2025-08-20T03:37:58ZrusOphthalmology Publishing GroupOftalʹmologiâ1816-50952500-08452015-07-01122434710.18008/1816-5095-2015-2-43-47237LONG-TERM OUTCOMES OF RETINAL DEGENERATIVE DISORDER TREATMENT WITH PEPTIDE BIOREGULATORSM. I. Razumovskiy0K. M. Pavlyuchenko1A. M. Razumovskaya2G. A. Albrecht St. Petersburg Scientific Practical Center of medical and social expertise, prosthetics and rehabilitation of disabled personsG. A. Albrecht St. Petersburg Scientific Practical Center of medical and social expertise, prosthetics and rehabilitation of disabled personsG. A. Albrecht St. Petersburg Scientific Practical Center of medical and social expertise, prosthetics and rehabilitation of disabled personsAim. To analyze long-term outcomes and efficacy of retinal degeneration treatment with Retinalamin.Patients and methods. Group I included 20 patients (40 eyes) with pigmentary retinal dystrophy (15 patients, 30 eyes) and retinal abiotrophy (5 patients, 10 eyes) who received treatment with Retinalamin for 5‑7 years. Group II included 11 patients (22 eyes) with pigmentary retinal dystrophy (9 patients, 18 eyes) and retinal abiotrophy (2 patients, 4 eyes) who received treatment with Retinalamin for 23‑25 years. Group III (controls) included 15 patients (30 eyes) with pigmentary retinal dystrophy (11 patients, 22 eyes) and retinal abiotrophy (4 patients, 8 eyes) who received traditional treatment (vasodilators, angioprotectors, antisclerotic agents, vitamins) for 25 years. Standard ophthalmological examination, i.e., visual acuity measurement, visual field test, refractometry, biomicroscopy, ophthalmoscopy, was performed.Results. First course of treatment with Retinalamin improved vision in 58.1 % of retinal degeneration patients. Visual fields improved in 64.5 % of cases. Repeated treatment courses (1‑2 times a year) for 23‑25 years preserved residual vision in 55.6 % of patients and object vision in 11.1 % of cases. In retinal abiotrophy patients, residual vision preserved in 100 % of cases.Conclusions. In retinal degenerations, Retinalamin improves vision and visual fields and decreases total area of absolute scotomas even after the first treatment course as well as preserves vision in prolonged use.https://www.ophthalmojournal.com/opht/article/view/242retinalaminlong-term outcomespigmentary degenerationabiotrophy
spellingShingle M. I. Razumovskiy
K. M. Pavlyuchenko
A. M. Razumovskaya
LONG-TERM OUTCOMES OF RETINAL DEGENERATIVE DISORDER TREATMENT WITH PEPTIDE BIOREGULATORS
Oftalʹmologiâ
retinalamin
long-term outcomes
pigmentary degeneration
abiotrophy
title LONG-TERM OUTCOMES OF RETINAL DEGENERATIVE DISORDER TREATMENT WITH PEPTIDE BIOREGULATORS
title_full LONG-TERM OUTCOMES OF RETINAL DEGENERATIVE DISORDER TREATMENT WITH PEPTIDE BIOREGULATORS
title_fullStr LONG-TERM OUTCOMES OF RETINAL DEGENERATIVE DISORDER TREATMENT WITH PEPTIDE BIOREGULATORS
title_full_unstemmed LONG-TERM OUTCOMES OF RETINAL DEGENERATIVE DISORDER TREATMENT WITH PEPTIDE BIOREGULATORS
title_short LONG-TERM OUTCOMES OF RETINAL DEGENERATIVE DISORDER TREATMENT WITH PEPTIDE BIOREGULATORS
title_sort long term outcomes of retinal degenerative disorder treatment with peptide bioregulators
topic retinalamin
long-term outcomes
pigmentary degeneration
abiotrophy
url https://www.ophthalmojournal.com/opht/article/view/242
work_keys_str_mv AT mirazumovskiy longtermoutcomesofretinaldegenerativedisordertreatmentwithpeptidebioregulators
AT kmpavlyuchenko longtermoutcomesofretinaldegenerativedisordertreatmentwithpeptidebioregulators
AT amrazumovskaya longtermoutcomesofretinaldegenerativedisordertreatmentwithpeptidebioregulators